Fred Wise and Marion Sulzberger first proposed the term “atopic dermatitis (AD)” in 1933 30. Despite nearly 100 years passing since then, numerous patients continue to suffer from AD. However, significant progress has been made in understanding the pathophysiology of AD over the past two decades. Several researchers have reported that AD encompasses a variety of clinical phenotypes; recently, Bieber introduced a multidimensional AD disease model that highlights a dynamic immune response divided into multiple components for preventive and therapeutic interventions 6. This improved understanding of the cellular and humoral elements involved in the pathophysiology of AD has expanded the possibility of exploring new therapeutic drugs.
Skin inflammation is associated with various types of immune cells, including Th1, Th2, Th17, and Th22 cells 31. The overexpression of Th2 cytokines such as IL-4, IL-13, and IL-31 is the most common cause of AD 32. Among the recently approved treatments for AD by the FDA and EMA, abrocitinib, a JAK1 inhibitor, has demonstrated promise for the treatment of moderate-to-severe AD 33. JAKs are a family of intracellular nonreceptor tyrosine kinases that activate signal transducers and activators of transcription (STATs) by transmitting signals from cytokines. IL-4 activates JAK1/JAK3-STAT6; IL-4 and IL-13 activate JAK1/JAK2/TYK2-STAT3 and 6; and IL-13 activates JAK1/JAK2-STAT1, 3, and 5 33.
Abrocitinib attenuates inflammation by reducing cytokine production. A recent meta-analysis of several studies revealed that abrocitinib significantly improved the skin condition and itchiness of patients in an entire long-term efficacy (LTE) population treated for ≥ 36 and ≥ 48 weeks with abrocitinib 34. However, some patients experienced adverse reactions, such as serious infections (herpes simplex, herpes zoster, and pneumonia), malignancy, thrombosis, and major adverse cardiovascular events 35. Additionally, other JAK inhibitors, such as baricitinib (a JAK1/JAK2 inhibitor) and upadacitinib (a JAK1 inhibitor), may also cause serious infections (tuberculosis, shingles, and others caused by bacteria, fungi, or viruses) and increase the risk of lymphoma and other cancers. Furthermore, both drugs may increase the risk of death in individuals aged > 50 years with one or more cardiovascular risk factors 35. Despite the proven efficacy of JAK inhibitors, treatment of AD remains challenging.
Because the incomplete resolution of inflammation is considered the underlying cause of numerous diseases, including AD, atherosclerosis, asthma, and arthritis, among other inflammatory diseases, achieving complete resolution is crucial for restoring immune homeostasis and maintaining overall health. Current treatment strategies mainly focus on providing temporary symptom relief by inhibiting pro-inflammatory mediators. However, they do not effectively eliminate foreign invaders or danger signals to achieve complete resolution. Moreover, these treatment methods can lead to unwanted side effects such as immunosuppression, which increases the risk of opportunistic infections. PLAG employed in the present study enhances the resolution of inflammation and strengthens the immune defense system by promoting natural endogenous resolution processes 36–38. Unlike conventional treatments, PLAG provides a fundamental approach that does not induce immunosuppression or secondary infections. Previous studies have demonstrated that PLAG effectively improves allergies and acute gouty inflammation in mouse models by resolving excessive inflammatory responses 22,39.
In the present study, we aimed to investigate the effects of PLAG in reducing DNCB-induced AD. Our results confirmed that the oral administration of PLAG effectively reduced AD symptoms by balancing the Th1/Th2 immune response, suppressing the recruitment of eosinophils and mast cells, and ameliorating the overexpression of IL-4, IL-13, IgE, TARC, and eotaxin. Notably, the efficacy of PLAG was comparable to that of abrocitinib, a drug commonly used to treat moderate-to-severe AD.
PLAG demonstrated superior improvement compared to abrocitinib in the phenotypic and histopathological evaluations. However, there was no significant difference between PLAG and abrocitinib in terms of the downregulation of IgE, IL-4, and IL-13 (Figs. 3 and 4). These results suggest that PLAG would modulate immune pathways distinct from those of abrocitinib and could potentially serve as a therapeutic agent for the effective management of refractory patients with AD who experience an unpredictable chronic disease course. Therefore, to better understand the mechanisms underlying the regulation of AD by PLAG, further studies should be conducted to explore its biochemical and functional effects at the molecular level.